Trod Medical, a medical device company with headquarters in Leuven (Belgium) and Tampa Bay area (USA), specializes in developing innovative ablation technologies, particularly Radio Frequency (RF) ablation devices. Their disruptive percutaneous RF device, the EncageTM, offers unmatched precision in ablating tissues, making it a major breakthrough in treatments where collateral tissue damage is a concern, such as prostate cancer. With around 240,000 new cases per year in the US alone, prostate cancer commonly leads to side effects like erectile dysfunction and urinary incontinence. Trod Medical's new approach to prostate cancer treatment minimizes the chances of these side effects by allowing closely targeted treatment of the affected areas. The technique is currently undergoing clinical validation.